Artivion Inc. Reports Strong 2024 Financial Results

Artivion Inc. ( (AORT) ) has released its Q4 earnings. Here is a breakdown of the information Artivion Inc. presented to its investors.

Artivion Inc., headquartered in Atlanta, Georgia, is a medical device company specializing in cardiac and vascular surgery solutions, particularly for aortic diseases. The company offers a range of products including aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, serving markets in over 100 countries worldwide.

In its latest earnings report, Artivion Inc. announced a 4% increase in revenue for the fourth quarter of 2024, reaching $97.3 million, compared to the same period in 2023. For the full year, the company reported a 10% increase in revenue, totaling $388.5 million. Despite a net loss of $16.5 million in the fourth quarter, the company achieved a non-GAAP net income of $0.2 million.

Key financial highlights include a 15% increase in adjusted EBITDA for the fourth quarter and a 32% increase for the full year, amounting to $17.6 million and $71.3 million, respectively. The company also generated $22.2 million in operating cash flow and $11.0 million in non-GAAP free cash flow for the year. Notably, Artivion received a Humanitarian Device Exemption from the FDA for its AMDS Hybrid Prosthesis and submitted the second module of its pre-market approval application.

Looking ahead, Artivion anticipates continued growth, projecting revenues between $420 million and $435 million for 2025, representing a 10% to 14% increase on a constant currency basis. The company also expects adjusted EBITDA growth of 18% to 28%, indicating a strong outlook for the upcoming year.